Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data

The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix

Prostate cancer (PC) is the most common cancer and the second leading cause of cancer death among men in the United States. Androgen deprivation therapy (ADT) such as injectable luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide) is the standard of care for PC patients. ADT treatment can suppress testosterone level to castrate level and delay the progression of the disease.

Relugolix is a recently approved oral GnRH antagonist. While the introduction of relugolix has offered a unique opportunity for patients with PC, it's vital to understand how it is being used in real-world.

Inclusion Criteria:

• Male with ≥ 1 diagnosis for PC
• Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
• Index date: the initiation date of relugolix
• At least 18 years old at the index date

Exclusion Criteria:

• had surgical castration (bilateral orchiectomy) any time before the index date